home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9601.ZIP
/
M9610126.TXT
< prev
next >
Wrap
Text File
|
1996-01-30
|
2KB
|
30 lines
Document 0126
DOCN M9610126
TI [New vaccines. What can we expect in the coming years?]
DT 9601
AU Bjune G; Nokleby HM; Avdeling for vaksine, Statens institutt for
folkehelse, Oslo.
SO Tidsskr Nor Laegeforen. 1995 Oct 10;115(24):3032-4. Unique Identifier :
AIDSLINE MED/96038696
AB There is an urgent need for new vaccines. The biotechnological
revolution has created new hope. However, developments are hampered by
inadequate basic knowledge about the immunology of infections, and lack
of coordination between public and commercial research and development
work on vaccines. Recombinant vaccines are an important step forward
when combined with new adjuvants, but the authorization of these
adjuvants for use in humans has been slow. Recombinant live vectors for
vaccine antigens circumvent this problem, but imply some risk in
HIV-infected people. Nucleic acid vaccines are met with strong emotional
resistance, because of many unanswered questions as to their safety.
Mucosal vaccines make quality control simpler, open up for a safer use
of live recombinant vectors and simplify delivery of the vaccine. New
vaccines marketed in the last decade are surprisingly old-fashioned.
Traditional ways of making vaccines have still not been abandoned.
DE Bacterial Vaccines/GENETICS/*SUPPLY & DISTRIBUTION English Abstract
Forecasting Human Viral Vaccines/GENETICS/*SUPPLY & DISTRIBUTION
JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).